We are live on ! Find out more
NGNE icon

Neurogene

45 hedge funds and large institutions have $53.5M invested in Neurogene in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

16% more capital invested

Capital invested by funds: $46.1M → $53.5M (+$7.36M)

2% more funds holding

Funds holding: 4445 (+1)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0.18% more ownership

Funds ownership: 3.69%3.88% (+0.18%)

48% less call options, than puts

Call options by funds: $268K | Put options by funds: $520K

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
1.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
16
Reduced
6
Closed
17
Calls
$268K
Puts
$520K
Net Calls
-$252K
Net Calls Change
+$56K

NGNE Hedge Fund Activity: Q3 2018 in Review

45 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2018, worth a combined $53.5M — up 16% from $46.1M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new NGNE positions and 17 closed out — a net gain of 1 holder — while 16 added to existing stakes and 6 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $3.29M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.58M sold.

  • 45 institutional investors held Neurogene (NGNE) as of Q3 2018, up from 44 in Q2 2018.
  • Funds reported $53.5M of Neurogene stock for Q3 2018, up 16% quarter-over-quarter.
  • 18 funds opened new Neurogene positions in Q3 2018 and 17 closed out, a net change of +1 holder.
  • The largest Neurogene buyer in Q3 2018 was EcoR1 Capital, an estimated $3.29M added.
  • The largest Neurogene seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.58M sold.

Based on aggregated 13F filings for Q3 2018.